The pathogenesis of inflammatory bowel disease (IBD) is still unclear. Immune dysfunction
may play a key role in the pathogenesis of IBD, in which the role of CD4+ T helper (Th) cells …

Secukinumab, ixekizumab and brodalumab are monoclonal antibody therapies that inhibit
interleukin (IL)-17 activity and are widely used for the treatment of psoriasis, psoriatic arthritis …

Objective: Few real-world studies have shown clear association between interleukin (IL)-17
inhibitors and inflammatory bowel disease (IBD) onset. This study investigated the reporting …

Spondyloarthritis (SpA) encompasses a heterogeneous group of chronic inflammatory
diseases that can affect both axial and peripheral joints, tendons and entheses. Among the …

IL-17 inhibitors (IL-17i) are medicines used to treat dermatological and rheumatic diseases
They belong to a class of medicines called biological disease-modifying anti-rheumatic …

Background Real-world data on the use of interleukin-17 (IL-17) inhibitors for the treatment
of psoriasis are limited. Objective To evaluate and compare the efficacy, safety, and drug …

Several gastrointestinal symptoms and chronic inflammatory bowel diseases (IBDs) have
been reported after therapy with IL‐17 inhibitors. To date, however, no study has shown a …

Introduction Interleukin 17 is a proinflammatory cytokine considered to play a significant role
in the immunopathogenesis of many chronic immune-mediated disorders. Interleukin 17 …

Background Comorbidities associated with psoriasis are well documented. However, few
studies have explored the comorbidity trajectories that patients with psoriasis commonly …

Abstract Background Interleukin (IL)-17 and T helper 17 (TH 17) cells, a distinct subset of
CD4+ T cells which promotes the expression of IL-17, mediate host defensive mechanisms …